Fasiglifam (Type 2 Diabetes)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis 15
3.1.4 Quality of Life 16
3.2 Symptoms 16
4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Diagnosis and Referrals 18
4.1.2 Treatment Guidelines 19
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26
6 Opportunity and Unmet Need 28
6.1 Overview 28
6.2 Unmet Needs 29
6.2.1 Drugs Providing Sustained Glycemic Control 29
6.2.2 Drugs with Non-Glycemic Benefits 30
6.2.3 Increased Patient Compliance 31
6.2.4 Drugs with Improved Side-Effect Profiles 32
6.2.5 Earlier Diagnosis 33
6.3 Unmet Needs Gap Analysis 34
6.4 Oral Therapy with Sustainable Efficacy 35
6.5 Oral Therapy Offering Weight Loss 35
6.6 Cardio-metabolic Therapy 36
6.7 Promotion of Type 2 Diabetes Drugs in Emerging Markets 36
7 Pipeline Assessment 37
7.1 Overview 37
7.2 Promising Drugs in Clinical Development 38
8 Fasiglifam (TAK-875) 43
8.1 Overview 43
8.2 Efficacy 44
8.3 Safety 45
8.4 Dosing and Formulation 46
8.5 Potential Clinical Positioning 46
8.6 Potential Commercial Positioning 46
8.7 Pricing and Reimbursement 47
8.8 SWOT Analysis 47
8.9 Forecast 48
9 Appendix 49
9.1 Bibliography 49
9.2 Abbreviations 51
9.3 Methodology 53
9.4 Forecasting Methodology 53
9.4.1 Diagnosed Type 2 Patients 53
9.4.2 Percent Drug-Treated Patients 54
9.4.3 Drugs Included in Each Therapeutic Class 54
9.4.4 General Pricing Assumptions 55
9.4.5 Pricing of Pipeline Agents 55
9.5 Physicians and Specialists Included in this Study 56
9.6 About the Authors 58
9.6.1 Analyst II – CVMD 58
9.6.2 Therapy Director – CVMD and Infectious Disease 58
9.6.3 Global Head of Healthcare 59
9.7 About GlobalData 60
9.8 Disclaimer 60